Accelerates wound healing, shortens healing time and reduces scar formation.
The only rEGF available in spray formulation in China, under NRDL.
A state category I New Drug based on genetic engineering technology.
Genetime® has accumulated over 20 years of clinical data, which proves its effectiveness and safeness without any side effects.
Genetime® is sterile formulation packaged aseptically and administers by spray, convenient for clinical practitioners and patients.
Genetime® is indicated for all wounds types found on the skin, allowing expansion to many indications.
Chronic wounds have the characteristics of high morbidity and high risk. Currently, there are about 100 million patients in China who need wound treatment every year, and about 30 million patients with severe cases.
As a wound healing factor, Genetime® has been widely used in clinical practice, such as burns, obstetrics and gynecology, difficult to heal wounds, oral ulcer, trauma surgery, surgical incision healing, radiotherapy department, laser cosmetic medicine, dressing room, etc.
The global wound care market is worth over US$10 billion, and nearly 10 million chronic wound patients will be added every year. The growth rate of the Chinese market is expected to be over 15%. In the future, with the aging of the population and the increase in the incidence of diabetes, the scale of the chronic wound market will continue to grow year by year.
